Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Accepted on 05 Jun 2025

Exploration on M2 macrophage-related biomarkers and candidate drug for glioblastoma using high-dimensional weighted gene co-expression network analysis

in Pharmacology of Anti-Cancer Drugs

Suyin Feng
Long Zhu
Jinyuan Gu
Kun Kou
Yongtai Liu
Guangmin Zhang
Hua Lu
Honglai Zhang
Runfeng Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587258

134 views

Case Report

Published on 05 Jun 2025

Case Report: Osimertinib-induced acute interstitial lung disease

in Pharmacology of Anti-Cancer Drugs

Zhiwu Lin
Liang Wu
Yang Yu
Jiudong Jiang
Yanchun Yang
Guibao Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1608733

563 views

Original Research

Published on 05 Jun 2025

Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo

in Pharmacology of Anti-Cancer Drugs

Essha Chatterjee
Ram Sharma
Biswajit Dey
Hoshiyar Singh
Aliva Naik
Anjesh Khan
Santanu Basak
Ankush Bansode
Ritika Sachdeva
Anamika Sharma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1544666

1,009 views

Mini Review

Published on 05 Jun 2025

Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications

in Pharmacology of Anti-Cancer Drugs

Chengwei Li
Xiaoyan Qi
Min Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572195

654 views

Original Research

Published on 04 Jun 2025

SPAG6 Promotes Multiple Myeloma Through Activation of the MAPK/ERK Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Junnan Li
Xinyu Yan
Li Ding
Jiaxiu Yin
Ping Li
Lin Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572621

550 views

Review

Published on 04 Jun 2025

Role and therapeutic potential of the NEDD4 family in breast cancer

in Pharmacology of Anti-Cancer Drugs

Xiaoxiao Zhang
Sijie Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587675

606 views

Original Research

Published on 04 Jun 2025

Pomolic acid induces ferroptosis-mediated cell death in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Wenbin Ji
Yanbin Zhang
Wenhao Ji
Hui Zhang
Biao Qin
Xiao-Liang Xing
Zaiqi Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1567942

827 views

Original Research

Accepted on 03 Jun 2025

Glycyrrhiza uralensis Fisch. Suppresses Cell Migration via ROS and JAK/STAT Signalling Pathways in Drosophila

in Pharmacology of Anti-Cancer Drugs

Fangfei Zhou
Meng Zhao
Yue Hu
Lingyu Kong
Sitong Wang
Haixia Zhang
Qingge Lu
Fanwu Wu
Chenxi Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1549920

144 views

Original Research

Published on 02 Jun 2025

SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma

in Pharmacology of Anti-Cancer Drugs

Yanzhi Wang
Huihui An
Yaou Zhang
Qing Rex Lyu
Zhe Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564682

920 views

Original Research

Published on 30 May 2025

Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches

in Pharmacology of Anti-Cancer Drugs

Yanrong Guo
Songyan Han
Qinxiang Guo
Jinfang Zhai
Xiaohui Ren
Shengshu Li
Jianchun Duan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1591643

662 views

Systematic Review

Published on 30 May 2025

Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Yijun Wang
Yicong Wang
Lei Wang
He Yuan
Yongai Yu
Daju Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566604

561 views

Original Research

Published on 30 May 2025

HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment

in Pharmacology of Anti-Cancer Drugs

Shihao Liang
Xiaoya Shao
Xueqiong Meng
Ying Cui
Chuanyue Sun
Jie Sun
Binghui Zhang
Guomin Shen
Ling Qin
Haiping Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1612916

497 views

Original Research

Published on 30 May 2025

Hypoxia-induced tRF-3Thr-CGT promotes hepatocellular carcinoma progression via mitochondrial energy metabolism remodeling dependent on the mtDNA-translation mechanism

in Pharmacology of Anti-Cancer Drugs

Xianzhi Qu
Buhan Liu
Duo Jin
Yue Ma
Mingjun Liu
Xiaoyu Yan
Jing Su
Lei Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1549373

558 views

Original Research

Published on 29 May 2025

A multimodal approach for establishing ACTL6A and ERCC1 as chemoresistance genes in locally advanced head and neck cancer

in Pharmacology of Anti-Cancer Drugs

Raushan Kumar Chaudhary
Prakash Patil
Vijith Vittal Shetty
Uday Venkat Mateti
Praveenkumar Shetty

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1541987

760 views

Original Research

Published on 29 May 2025

Polypharmacy, drug–drug interactions and adverse drug reactions in older Chinese cancer patients: evidence from CHARLS

in Pharmacology of Anti-Cancer Drugs

Zijun Yan
Ke-qin Fan
Ting Yu
Ning Su
Yan Zou
Liangjing Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1579023

931 views

Original Research

Accepted on 27 May 2025

Targeted Degradation of EGFR 19Del by Protac Suppresses Tumor Growth in Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Lianhua Piao
Ying Gao
Yangyang Su
Qihui Li
Xiaofeng Yuan
Wangqiu He
Wanzhou Zhao
Janne Kulpakko
Pei-Chieng Cha
Shan Chang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1604661

236 views